The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia

The Schizophrenia Working Group of the Psychiatric Genomics Consortium 2,

Research output: Contribution to journalArticle

Abstract

A recent development in the genetic architecture of schizophrenia suggested that an omnigenic model may underlie the risk for this disorder. The aim of our study was to use polygenic profile scoring to quantitatively assess whether a number of experimentally derived sets would contribute to the disorder above and beyond the omnigenic effect. Using the PGC2 secondary analysis schizophrenia case-control cohort (N = 29,125 cases and 34,836 controls), a robust polygenic signal was observed from gene sets based on TCF4, FMR1, upregulation from MIR137 and downregulation from CHD8. Additional analyses revealed a constant floor effect in the amount of variance explained, consistent with the omnigenic model. Thus, we report that putative core gene sets showed a significant effect above and beyond the floor effect that might be linked with the underlying omnigenic background. In addition, we demonstrate a method to quantify the contribution of specific gene sets within the omnigenic context.

Original languageEnglish (US)
JournalNeuropsychopharmacology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Schizophrenia
Genes
Up-Regulation
Down-Regulation

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia. / The Schizophrenia Working Group of the Psychiatric Genomics Consortium 2,.

In: Neuropsychopharmacology, 01.01.2019.

Research output: Contribution to journalArticle

The Schizophrenia Working Group of the Psychiatric Genomics Consortium 2,. / The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia. In: Neuropsychopharmacology. 2019.
@article{a19ec67583004ae7b270af8748f49c27,
title = "The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia",
abstract = "A recent development in the genetic architecture of schizophrenia suggested that an omnigenic model may underlie the risk for this disorder. The aim of our study was to use polygenic profile scoring to quantitatively assess whether a number of experimentally derived sets would contribute to the disorder above and beyond the omnigenic effect. Using the PGC2 secondary analysis schizophrenia case-control cohort (N = 29,125 cases and 34,836 controls), a robust polygenic signal was observed from gene sets based on TCF4, FMR1, upregulation from MIR137 and downregulation from CHD8. Additional analyses revealed a constant floor effect in the amount of variance explained, consistent with the omnigenic model. Thus, we report that putative core gene sets showed a significant effect above and beyond the floor effect that might be linked with the underlying omnigenic background. In addition, we demonstrate a method to quantify the contribution of specific gene sets within the omnigenic context.",
author = "{The Schizophrenia Working Group of the Psychiatric Genomics Consortium 2,} and Alexandros Rammos and Gonzalez, {Lara A.Neira} and Daniel Weinberger and Mitchell, {Kevin J.} and Nicodemus, {Kristin K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41386-019-0410-z",
language = "English (US)",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia

AU - The Schizophrenia Working Group of the Psychiatric Genomics Consortium 2,

AU - Rammos, Alexandros

AU - Gonzalez, Lara A.Neira

AU - Weinberger, Daniel

AU - Mitchell, Kevin J.

AU - Nicodemus, Kristin K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A recent development in the genetic architecture of schizophrenia suggested that an omnigenic model may underlie the risk for this disorder. The aim of our study was to use polygenic profile scoring to quantitatively assess whether a number of experimentally derived sets would contribute to the disorder above and beyond the omnigenic effect. Using the PGC2 secondary analysis schizophrenia case-control cohort (N = 29,125 cases and 34,836 controls), a robust polygenic signal was observed from gene sets based on TCF4, FMR1, upregulation from MIR137 and downregulation from CHD8. Additional analyses revealed a constant floor effect in the amount of variance explained, consistent with the omnigenic model. Thus, we report that putative core gene sets showed a significant effect above and beyond the floor effect that might be linked with the underlying omnigenic background. In addition, we demonstrate a method to quantify the contribution of specific gene sets within the omnigenic context.

AB - A recent development in the genetic architecture of schizophrenia suggested that an omnigenic model may underlie the risk for this disorder. The aim of our study was to use polygenic profile scoring to quantitatively assess whether a number of experimentally derived sets would contribute to the disorder above and beyond the omnigenic effect. Using the PGC2 secondary analysis schizophrenia case-control cohort (N = 29,125 cases and 34,836 controls), a robust polygenic signal was observed from gene sets based on TCF4, FMR1, upregulation from MIR137 and downregulation from CHD8. Additional analyses revealed a constant floor effect in the amount of variance explained, consistent with the omnigenic model. Thus, we report that putative core gene sets showed a significant effect above and beyond the floor effect that might be linked with the underlying omnigenic background. In addition, we demonstrate a method to quantify the contribution of specific gene sets within the omnigenic context.

UR - http://www.scopus.com/inward/record.url?scp=85066106747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066106747&partnerID=8YFLogxK

U2 - 10.1038/s41386-019-0410-z

DO - 10.1038/s41386-019-0410-z

M3 - Article

C2 - 31078131

AN - SCOPUS:85066106747

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -